Moneycontrol PRO
Upcoming Webinar:Moneycontrol Pro in association with Quants League Sep'21 Edition brings to you to 5-Days Live Algorithmic Options Trading Virtual Conference. Register Now!

Buy Abbott India; target of Rs 7530: Centrum

Centrum is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 7530 in its research report dated May 15, 2018.

May 23, 2018 / 03:58 PM IST
  • bselive
  • nselive
Todays L/H

Centrum's research report on Abbott India

AIL’s EBIDTA for Q4FY18 was lower than our expectations whereas net profit was higher than our expectations. The pharma major’s revenue grew 10% YoY, margin improved 470bps to 13.5% and net profit grew 138% YoY. That said, the company’s eleven leading brands grew faster than the market and are likely to drive future growth.


We maintain our Buy rating on AIL with a TP of Rs7,530 based on 24x March’20E EPS of Rs313.6.  we have revised FY19E and FY20E EPS by 6% and 7% respectively. We expect AIL to perform well due to its strong brands, new product launches and presence in the high-margin vaccine segment.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 23, 2018 03:58 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark